Smith & Nephew plc (NYSE:SNN) Shares Sold by Moran Wealth Management LLC

Moran Wealth Management LLC cut its position in shares of Smith & Nephew plc (NYSE:SNN - Free Report) by 39.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 115,815 shares of the medical equipment provider's stock after selling 74,858 shares during the quarter. Moran Wealth Management LLC's holdings in Smith & Nephew were worth $2,847,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. US Bancorp DE raised its holdings in Smith & Nephew by 19.2% in the third quarter. US Bancorp DE now owns 11,167 shares of the medical equipment provider's stock valued at $348,000 after buying an additional 1,802 shares during the period. Crossmark Global Holdings Inc. raised its stake in shares of Smith & Nephew by 63.7% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 112,859 shares of the medical equipment provider's stock valued at $3,515,000 after acquiring an additional 43,924 shares during the period. Oppenheimer Asset Management Inc. lifted its holdings in shares of Smith & Nephew by 5.6% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 17,218 shares of the medical equipment provider's stock valued at $536,000 after acquiring an additional 920 shares in the last quarter. Pathstone Holdings LLC lifted its holdings in shares of Smith & Nephew by 14.8% during the 3rd quarter. Pathstone Holdings LLC now owns 48,903 shares of the medical equipment provider's stock valued at $1,523,000 after acquiring an additional 6,317 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in Smith & Nephew by 29.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 27,199 shares of the medical equipment provider's stock worth $847,000 after purchasing an additional 6,164 shares during the period. 25.64% of the stock is currently owned by hedge funds and other institutional investors.

Smith & Nephew Stock Performance

Shares of SNN stock opened at $29.87 on Wednesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.51 and a quick ratio of 1.11. The company's fifty day moving average price is $26.10 and its two-hundred day moving average price is $27.17. The firm has a market capitalization of $13.06 billion, a P/E ratio of 13.83, a P/E/G ratio of 1.26 and a beta of 0.83. Smith & Nephew plc has a 12 month low of $23.65 and a 12 month high of $31.72.

Smith & Nephew Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Wednesday, May 28th. Investors of record on Friday, March 28th will be issued a $0.447 dividend. The ex-dividend date is Friday, March 28th. This represents a yield of 2.5%. This is an increase from Smith & Nephew's previous semi-annual dividend of $0.29. Smith & Nephew's dividend payout ratio is currently 41.20%.

Analyst Upgrades and Downgrades

A number of brokerages have commented on SNN. StockNews.com upgraded Smith & Nephew from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, February 26th. Canaccord Genuity Group reissued a "hold" rating and set a $27.00 price target on shares of Smith & Nephew in a research report on Wednesday, February 26th. Three research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Smith & Nephew currently has a consensus rating of "Moderate Buy" and an average price target of $27.00.

Remove Ads

About Smith & Nephew

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.